City of Hope | Strategic Alliance Partners

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.

Pharmacy Times interviews Robert R. Jeng, MD, on how the gut microbiome may influence CAR T-cell therapy response, toxicity, and persistence, as well as the challenges and future potential of microbiome-based interventions in improving patient outcomes.

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Enrique Velazquez Villarreal, MD, PhD, used a conversational AI platform to unify microbiome, genomic, clinical, and social determinants of health data for colorectal cancer research.

New findings on nodal radiation for breast cancer patients highlight the importance of lymph node involvement and tumor size in treatment decisions.

Discover how GLP-1 receptor agonists may benefit breast cancer patients by promoting weight loss and improving long-term health outcomes.

Explore the latest insights on breast cancer treatment, focusing on radiation, endocrine therapy, and the role of pharmacists in patient care.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma.

Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care.

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.

Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.

Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.

Leukemia biology may predict patterns of blinatumomab failure after initial response.

Jose Tinajero discusses how certain mutations can be indicators of blinatumomab treatment failure in patients with B-cell acute lymphoblastic leukemia.

New research by City of Hope suggests the biotherapeutic product, CBM588, adjusts people’s microbiome, possibly leading to enhanced effectiveness of FDA-approved cancer immunotherapies.

Research focused on potentially reducing hypoglycemic episodes, why more men might have diabetes than women, and targeting glucose control.

Trial results published today in Nature Medicine and a phase 1b trial using the same CAR T cell therapy has opened.

Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.